Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
暂无分享,去创建一个
Derick R. Peterson | K. Hao | H. Ostrer | G. Pandey | M. Sydes | R. Eeles | D. Dearnaley | A. Dunning | R. Stock | N. Stone | P. Pharoah | M. Ahsen | C. West | N. Usmani | M. Parliament | B. Rosenstein | N. Burnet | S. Bentzen | E. Hall | S. Gulliford | D. Peterson | S. Kerns | L. Fachal | A. Vega | A. Gómez-Caamaño | S. Singhal | G. Barnett | R. Elliott | L. Dorling | P. Peleteiro | A. Carballo | Ramón Lobato-Busto | H. Tsuji | M. Janelsins | T. Imai | A. Baran | S. Saito | Michelle Hollenberg | A. D. Narzo | M. Aguado-Barrera | K. DeRuyck | Miguel E. Aguado-Barrera
[1] P. Donnelly,et al. A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.
[2] J. Stanford,et al. Long-term functional outcomes after treatment for localized prostate cancer. , 2013, The New England journal of medicine.
[3] R. Eeles,et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects , 2005, British Journal of Cancer.
[4] M. Sydes,et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] E. Schadt,et al. A Nasal Brush-based Classifier of Asthma Identified by Machine Learning Analysis of Nasal RNA Sequence Data , 2017, bioRxiv.
[6] Hans L. Oestreicher,et al. Supplementary notes , 2018, Much Ado about Nothing.
[7] Joseph O Deasy,et al. STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] H. Deckmyn,et al. Platelet adhesion to collagen. , 2011, Thrombosis research.
[9] J. Ioannidis,et al. Meta-analysis methods for genome-wide association studies and beyond , 2013, Nature Reviews Genetics.
[10] Jen-Tzung Chien,et al. Radiation Therapy Outcomes Models in the Era of Radiomics and Radiogenomics: Uncertainties and Validation. , 2018, International journal of radiation oncology, biology, physics.
[11] Alison M. Dunning,et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype , 2009, Nature Reviews Cancer.
[12] Jon Wakefield,et al. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. , 2007, American journal of human genetics.
[13] M. Kanai,et al. Genome-wide association study identifies 112 new loci for body mass index in the Japanese population , 2017, Nature Genetics.
[14] M. Hauer-Jensen,et al. Radiation enteropathy—pathogenesis, treatment and prevention , 2014, Nature Reviews Gastroenterology &Hepatology.
[15] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[16] W. De Neve,et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. , 2004, International journal of radiation oncology, biology, physics.
[17] Richard Stock,et al. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer , 2016, EBioMedicine.
[18] Yurii S. Aulchenko,et al. ProbABEL package for genome-wide association analysis of imputed data , 2010, BMC Bioinformatics.
[19] LENT SOMA scales for all anatomic sites. , 1995, International journal of radiation oncology, biology, physics.
[20] H. Ostrer,et al. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. , 2013, The Journal of urology.
[21] Alison M Dunning,et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1 , 2014, Nature Genetics.
[22] D. Dearnaley,et al. Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. , 2012, European journal of cancer.
[23] Dennis J. Hazelett,et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[24] Annie Gao,et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.
[25] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[26] J. Rosenbloom,et al. Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies , 2010, Annals of Internal Medicine.
[27] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, Genome Biology.
[28] J. Michael Cherry,et al. ENCODE data at the ENCODE portal , 2015, Nucleic Acids Res..
[29] Zachary A. Szpiech,et al. Genome-wide association studies in diverse populations , 2010, Nature Reviews Genetics.
[30] Michael Boehnke,et al. LocusZoom: regional visualization of genome-wide association scan results , 2010, Bioinform..
[31] Daniel Marbach,et al. Fast and Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary Statistics , 2016, PLoS Comput. Biol..
[32] P. D. de Groot,et al. Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. , 2010, Blood.
[33] M. Spitz,et al. Mutagen sensitivity has high heritability: evidence from a twin study. , 2006, Cancer research.
[34] K. D. Sørensen,et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.
[35] Matthias Egger,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.
[36] Annie Gao,et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. , 2012, The Lancet. Oncology.
[37] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[38] A. Molteni, J. E. Moulder, E. F. Cohen, W. F. Ward, B,et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker , 2000 .
[39] Andrew P Morris,et al. Multi-ethnic genome-wide association study identifies novel locus for type 2 diabetes susceptibility , 2016, European Journal of Human Genetics.
[40] M. Sydes,et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[41] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[42] J. Vaňásek,et al. Late toxicity after conformal and intensity‐modulated radiation therapy for prostate cancer: Impact of previous surgery for benign prostatic hyperplasia , 2010, International journal of urology : official journal of the Japanese Urological Association.
[43] B. Becker,et al. How meta-analysis increases statistical power. , 2003, Psychological methods.
[44] W. Vainchenker,et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. , 2004, Blood.
[45] Y. Li,et al. Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations , 2014, Genome Medicine.
[46] P. Lambin,et al. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).
[47] E. Cohen,et al. Noncontinuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy , 1997, Bone Marrow Transplantation.
[48] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[49] P. Lambin,et al. Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era , 2017, Front. Oncol..
[50] R. Stock,et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. , 2006, International journal of radiation oncology, biology, physics.
[51] N G Burnet,et al. Radiosensitivity, radiogenomics and RAPPER. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).
[52] H. Ostrer,et al. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. , 2013, Radiotherapy and Oncology.
[53] Richard Stock,et al. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.
[54] J. Hendry,et al. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. , 2002, International journal of radiation oncology, biology, physics.
[55] Y. Yamada,et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[56] John T. Wei,et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.
[57] J. Ioannidis,et al. STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement. , 2009, Genetic epidemiology.
[58] E. Gore,et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. , 2012, International journal of radiation oncology, biology, physics.
[59] M. Sydes,et al. Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397) , 2010, International journal of radiation oncology, biology, physics.
[60] A. Dunning,et al. Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. , 2012, International journal of radiation oncology, biology, physics.
[61] Nawaid Usmani,et al. The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention. , 2015, Seminars in radiation oncology.
[62] S. Tucker,et al. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[63] P. Carroll,et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. , 1995, International journal of radiation oncology, biology, physics.